BioInvent International AB (BINV) AI Stock Analysis

• Market Cap: kr1.83B
• Dividend Yield: N/A
• Average Volume (3M): 91.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: 533.73%
• EPS Growth: 20.92%
• Country: SE
• Employees: 118
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.96
• Shares Outstanding: 65,804,360
• 10 Day Avg. Volume: 84,851
• 30 Day Avg. Volume: 91,723
• PEG Ratio: -0.20
• Price to Book (P/B): 2.86
• Price to Sales (P/S): 56.69
• P/FCF Ratio: -6.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: kr28.00 ▼(-1.58% Downside)

BioInvent International AB's overall score is driven by strong revenue growth and strategic focus on clinical programs. However, ongoing profitability challenges, weak technical indicators, and a negative P/E ratio weigh heavily on the stock's attractiveness.

Positive Factors

Revenue Growth

The substantial increase in net sales indicates strong revenue growth, driven by strategic partnerships and milestone payments, enhancing BioInvent's market position and financial health.

Financial Stability

Having substantial liquid funds and secured financing through Q1 2027 provides BioInvent with the financial stability needed to continue its R&D efforts and support long-term growth.

Clinical Program Success

Successful clinical outcomes for BI-1808 enhance BioInvent's competitive advantage in immuno-oncology, potentially leading to new market opportunities and partnerships.

Negative Factors

Profitability Challenges

Ongoing profitability challenges, as evidenced by significant losses, could hinder BioInvent's ability to reinvest in R&D and limit its financial flexibility.

Increased Operating Costs

Rising operating costs, particularly in lead programs, may pressure margins and require careful management to maintain financial health and operational efficiency.

Negative Cash Flow

Negative cash flow indicates that BioInvent is spending more than it earns, which could impact its ability to fund operations and invest in future growth without additional financing.

BioInvent International AB Business Overview & Revenue Model

Company Description

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

How the Company Makes Money

BioInvent International AB generates revenue through a combination of product development partnerships, licensing agreements, and potential milestone payments from collaborations with larger pharmaceutical companies. The company often enters into strategic alliances with other biotech and pharmaceutical firms to co-develop its drug candidates, which can provide upfront payments and funding for research and development. Additionally, BioInvent may receive royalties on future sales of products developed from these collaborations. Their revenue model is heavily reliant on the successful advancement of their therapeutic candidates through clinical trials and subsequent commercialization, which can significantly increase earnings based on the success of their research endeavors and market acceptance of their therapies.

BioInvent International AB Financial Statement Overview

Summary

BioInvent International AB shows strong revenue growth but struggles with profitability and cash flow. The low debt-to-equity ratio is positive, but negative returns on equity and cash flow are concerning.

Income Statement

BioInvent International AB shows a significant revenue growth rate of 318.21% in the TTM period, indicating strong top-line expansion. However, the company struggles with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The consistent negative margins highlight ongoing challenges in achieving operational efficiency and profitability.

Balance Sheet

The company's balance sheet reflects a low debt-to-equity ratio of 0.016, suggesting minimal leverage and a conservative capital structure. However, the negative return on equity indicates that the company is not generating profits from its equity base, which is a concern for investors seeking returns.

Cash Flow

BioInvent's cash flow statement reveals a negative operating cash flow and free cash flow, indicating cash outflows from operations. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with net income, but the negative growth in free cash flow is a concern for future liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	244.85M	44.69M	71.46M	326.13M	19.38M	147.37M
Gross Profit	241.53M	44.69M	71.46M	326.13M	19.38M	147.37M
EBITDA	-314.75M	-409.38M	-312.71M	-27.13M	-263.32M	-63.99M
Net Income	-323.94M	-429.38M	-330.30M	-34.09M	-278.96M	-76.67M
Balance Sheet
Total Assets	785.82M	989.24M	1.40B	1.71B	1.45B	802.64M
Cash, Cash Equivalents and Short-Term Investments	690.46M	867.16M	1.07B	1.02B	1.08B	729.27M
Total Debt	10.69M	17.41M	23.24M	26.96M	28.37M	11.60M
Total Liabilities	102.80M	103.42M	90.45M	106.09M	80.32M	59.14M
Stockholders Equity	683.02M	885.82M	1.31B	1.61B	1.37B	743.50M
Cash Flow
Free Cash Flow	-262.35M	-390.50M	-355.00M	-53.60M	-259.10M	-69.32M
Operating Cash Flow	-255.51M	-380.47M	-341.69M	-41.23M	-245.84M	-62.62M
Investing Cash Flow	39.10M	564.35M	59.68M	-628.85M	-467.54M	-6.70M
Financing Cash Flow	-8.96M	-8.46M	23.14M	273.49M	894.87M	644.62M

BioInvent International AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 28.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BINV, the sentiment is Negative. The current price of 28.45 is below the 20-day moving average (MA) of 28.57, below the 50-day MA of 29.22, and below the 200-day MA of 31.94, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 42.95 is Neutral, neither overbought nor oversold. The STOCH value of 23.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BINV.

BioInvent International AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	76 Outperform	kr2.92B	4.46	167.77%	―	2687.51%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BINV	47 Neutral	kr1.83B	-5.78	-36.52%	―	533.73%	20.92%
XSPRAY	47 Neutral	kr1.24B	-5.01	-35.03%	―	―	25.14%
VICO	45 Neutral	kr2.76B	-5.22	-71.87%	―	-91.85%	-6.65%
HNSA	41 Neutral	kr2.84B	-3.21	―	―	-5.69%	21.58%
CANTA	31 Underperform	€1.02B	8.21	81.19%	―	―	―

BioInvent International AB Corporate Events

BioInvent Publishes Promising Early Data for BI-1607 in Cancer Treatment

BioInvent International AB has published preclinical and early Phase 1 data for BI-1607, a novel FcγRIIB-blocking monoclonal antibody, in the journal Clinical Cancer Research. The study shows promising disease control in HER2-positive advanced solid tumors, with 78% of patients experiencing stable disease. Although the BI-1607 program is currently paused, the data supports the potential of Fcγ monoclonal antibodies in enhancing cancer treatment efficacy, particularly in combination with other therapeutic antibodies like trastuzumab.

BioInvent’s BI-1808 Receives Positive EMA Opinion for Orphan Drug Designation

BioInvent International AB announced that the European Medicines Agency’s Committee for Orphan Medicinal Products has given a positive opinion for Orphan Drug Designation to its investigational product BI-1808 for treating Cutaneous T-cell Lymphoma (CTCL). This designation is expected to promote the development of drugs for rare diseases, offering incentives like protocol assistance and market exclusivity. BI-1808 has shown promising clinical activity with a 100% disease control rate in a Phase 2a trial, and it is well-tolerated with mild to moderate adverse events. The European Commission is anticipated to grant the designation within 30 days, which underscores BioInvent’s commitment to advancing novel immunotherapies for underserved hematologic malignancies.

BioInvent’s BI-1910 Shows Promise in Phase 1 Trials for Solid Tumors

BioInvent International AB announced promising Phase 1 clinical data for its TNFR2 agonist antibody, BI-1910, presented at the SITC 2025 Annual Meeting. The study showed that BI-1910 can activate immune responses and induce disease control in patients with advanced solid tumors, with 12 out of 26 patients achieving stable disease. Despite these positive results, BioInvent has paused the development of BI-1910 to focus on its more advanced program, BI-1808, which is progressing in Phase 2 clinical development.

BioInvent to Present Promising Phase 2a Data at ASH 2025

BioInvent International AB announced that it will present early Phase 2a data from its ongoing trial of a triple combination therapy involving BI-1206, rituximab, and Calquence for treating non-Hodgkin’s lymphoma (NHL) at the ASH 2025 meeting. The data indicates that the combination is safe and well-tolerated, with promising efficacy signals, and the company is optimistic about advancing to the next phase to potentially improve patient outcomes and the standard of care.

BioInvent to Present Promising BI-1808 Data at ASH 2025

BioInvent International AB announced the presentation of updated Phase 2a data for its BI-1808 monotherapy at the 2025 ASH Annual Meeting. The data highlights the treatment’s promising efficacy and safety profile in cutaneous T-cell lymphoma (CTCL), with no severe adverse events reported and a high disease control rate. BI-1808 has received Fast Track and Orphan Drug Designations from the FDA, underscoring its potential impact on patients with unmet medical needs.

BioInvent Prioritizes Advanced Programs to Boost Cancer Therapy Development

BioInvent International AB announced a strategic shift to prioritize its advanced clinical programs, BI-1206 and BI-1808, aiming to accelerate their development and enhance value creation. The company is set to achieve several key milestones in the second half of 2025, including additional data releases for its treatments targeting cutaneous T-cell lymphoma and non-Hodgkin’s lymphoma, as well as a Phase 2a study for solid tumors. This strategic focus is expected to strengthen BioInvent’s position in the immuno-oncology sector and potentially impact stakeholders positively by advancing promising cancer therapies.

BioInvent to Present Interim Report for January-September 2025

BioInvent International AB has announced an upcoming presentation of its interim report for January to September 2025, scheduled for October 29, 2025. The presentation will be led by CEO Martin Welschof and CFO Stefan Ericsson, providing insights into the company’s financial performance and ongoing clinical programs. Stakeholders can participate via webcast or teleconference, highlighting BioInvent’s commitment to transparency and engagement with investors and analysts.

BioInvent and Transgene’s BT-001 Shows Promising Results in Cancer Treatment

BioInvent International AB and Transgene have announced positive clinical results for their oncolytic virus BT-001, which shows promising antitumoral activity in combination with pembrolizumab in patients with advanced refractory tumors. The data presented at the ESMO 2025 Annual Meeting indicate that BT-001 is well tolerated and effective in shrinking tumors, supporting further development across a range of solid tumors. This development could enhance treatment options for cancer patients, particularly those with limited alternatives, by transforming cold tumors into immunologically active ones.

BioInvent and Transgene Reveal Promising BT-001 Clinical Data at ESMO 2025

BioInvent International AB and Transgene have announced the presentation of translational data and updated clinical results for their oncolytic virus BT-001 at the ESMO 2025 Annual Meeting. The Phase 1 study results indicate that BT-001, in combination with pembrolizumab, shows promise as a treatment for advanced refractory tumors, demonstrating tumor shrinkage in both injected and non-injected lesions. This development could enhance the response to immune checkpoint inhibitors in refractory patients, potentially impacting the company’s position in the cancer immunotherapy market.

BioInvent Launches Phase 2a Trial for BI-1206 in NSCLC and Uveal Melanoma

BioInvent International AB has initiated a Phase 2a clinical trial for its drug candidate BI-1206, in combination with pembrolizumab, targeting advanced or metastatic non-small cell lung cancer (NSCLC) and uveal melanoma. This trial follows promising results from Phase 1, where BI-1206 demonstrated safety and clinical activity, offering hope for overcoming resistance mechanisms in cancer treatment and potentially expanding its use across various indications where pembrolizumab is approved.

BioInvent to Present Phase 1 Data for BI-1910 at SITC

BioInvent International AB announced that it will present updated Phase 1 clinical data for BI-1910, a TNFR2 agonist for treating solid tumors, at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting. Despite the successful completion of the single agent dose escalation phase without notable adverse events, BioInvent has decided to pause the development of BI-1910 following a strategic review to focus on advancing other programs, such as BI-1808 and BI-1206. The announcement highlights BioInvent’s strategic shift and its potential implications for stakeholders, as TNFR2 represents a promising target for cancer immunotherapy.